dostęp otwarty

Tom 13, Nr 6 (2016)
Repetytorium z kardiologii
Pobierz cytowanie

Ocena czynności nerek u pacjenta z chorobą układu sercowo-naczyniowego

Longin Niemczyk, Stanisław Niemczyk
Choroby Serca i Naczyń 2016;13(6):445-466.

dostęp otwarty

Tom 13, Nr 6 (2016)
Repetytorium z kardiologii

Streszczenie

Brak

Streszczenie

Brak
Pobierz cytowanie
Informacje o artykule
Tytuł

Ocena czynności nerek u pacjenta z chorobą układu sercowo-naczyniowego

Czasopismo

Choroby Serca i Naczyń

Numer

Tom 13, Nr 6 (2016)

Strony

445-466

Rekord bibliograficzny

Choroby Serca i Naczyń 2016;13(6):445-466.

Autorzy

Longin Niemczyk
Stanisław Niemczyk

Referencje (54)
  1. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19): 1527–1539.
  2. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35(3): 681–689.
  3. Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731): 2073–2081.
  4. Król E, Rutkowski B, Czarniak P, et al. Early detection of chronic kidney disease: results of the PolNef study. Am J Nephrol. 2009; 29(3): 264–273.
  5. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001; 134(8): 629–636.
  6. Astor B, Matsushita K, Gansevoort R, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International. 2011; 79(12): 1331–1340.
  7. Dunkler D, Kohl M, Teo KK, et al. ONTARGET Investigators, ONTARGET Investigators, ONTARGET Investigators, ONTARGET investigators, Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators, OnTARGET/TRANSCEND Investigators, Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET), Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators, ONTARGET and TRANSCEND Investigators, ONTARGET investigators, ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547–1559.
  8. Zannad F, McMurray JJV, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11–21.
  9. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004; 351(6): 585–592.
  10. Garwicz D, Karlman M. Early recognition of reverse pseudohyperkalemia in heparin plasma samples during leukemic hyperleukocytosis can prevent iatrogenic hypokalemia. Clin Biochem. 2012; 45(18): 1700–1702.
  11. Ohashi N, Minemura S, Togawa A, et al. A case of hypokalemia-induced fatal arrhythmia caused by indapamide in an anorexic elderly patient. Clin Exp Nephrol. 2011; 15(5): 761–764.
  12. Skelding KA, Best PJM, Bartholomew BA, et al. Validation of a predictive risk score for radiocontrast-induced nephropathy following percutaneous coronary intervention. J Invasive Cardiol. 2007; 19(5): 229–233.
  13. Momeni A, Mirhoseini M, Beigi FM, et al. Effect of N-acetyl cysteine in prevention of contrast nephropathy on patients under intravenous pyelography and contrast CT. Adv Biomed Res. 2012; 1: 28.
  14. Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol. 2009; 103(12): 1657–1662.
  15. Maioli M, Toso A, Gallopin M, et al. Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention. J Cardiovasc Med (Hagerstown). 2010; 11(6): 444–449.
  16. McCullough P. Contrast-Induced Acute Kidney Injury. Journal of the American College of Cardiology. 2008; 51(15): 1419–1428.
  17. Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010; 121(19): 2117–2122.
  18. Thomas M. Early detection of patients with kidney disease. Nephrology. 2007; 12(s1): S37–S40.
  19. Eknoyan G. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1): S1–S266.
  20. Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. Am Fam Physician. 2004; 70(6): 1091–1097.
  21. Cirillo M. Evaluation of glomerular filtration rate and of albuminuria/proteinuria. J Nephrol. 2010; 23(2): 125–132.
  22. Kidney Disease: Improving Global Outcomes (KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int (Suppl. 2013; 3: 19–62.
  23. Kidney Disease: Improving Global Outcomes (KDIGO Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int (Suppl. 2012; 2: 337–414.
  24. Branten AJW, Vervoort G, Wetzels JFM. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant. 2005; 20(4): 707–711.
  25. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 1990; 38(1): 167–184.
  26. Duncker D, Oswald H, Gardiwal A, et al. Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine. J Cardiovasc Pharmacol Ther. 2013; 18(2): 109–112.
  27. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139(2): 137–147.
  28. Eastwood JB, Kerry SM, Plange-Rhule J, et al. Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations. Nephrol Dial Transplant. 2010; 25(7): 2178–2187.
  29. Daniel JP, Chantrel F, Offner M, et al. Comparison of cystatin C, creatinine and creatinine clearance vs. GFR for detection of renal failure in renal transplant patients. Ren Fail. 2004; 26(3): 253–257.
  30. Hsu CY, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int. 2002; 61(5): 1567–1576.
  31. Fontseré N, Bonal J, Navarro M, et al. A comparison of prediction equations for estimating glomerular filtration rate in adult patients with chronic kidney disease stages 4-5. Effect of nutritional status and age. Nephron Clin Pract. 2006; 104(4): c160–c168.
  32. Toto RD, Kirk KA, Coresh J, et al. Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study. J Am Soc Nephrol. 1997; 8(2): 279–287.
  33. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31–41.
  34. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997; 51(6): 1908–1919.
  35. Kuan Y, Hossain M, Surman J, et al. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant. 2005; 20(11): 2394–2401.
  36. Lin J, Knight EL, Hogan ML, et al. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003; 14(10): 2573–2580.
  37. Vervoort G. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrology Dialysis Transplantation. 2002; 17(11): 1909–1913.
  38. Bevc S, Hojs R, Ekart R, et al. Simple cystatin C formula compared to sophisticated CKD-EPI formulas for estimation of glomerular filtration rate in the elderly. Ther Apher Dial. 2011; 15(3): 261–268.
  39. Hojs R, Bevc S, Ekart R, et al. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant. 2006; 21(7): 1855–1862.
  40. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol. 2007; 27(2): 197–205.
  41. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006; 145(4): 237–246.
  42. Deo R, Fyr CL, Fried LF, et al. Health ABC study. Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008; 155(1): 62–68.
  43. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit. 2006; 28(3): 326–331.
  44. Schück O, Teplan V, Sibová J, et al. Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment. Int J Clin Pharmacol Ther. 2004; 42(2): 93–97.
  45. Watanabe S, Okura T, Kurata M, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens. 2006; 28(5): 451–461.
  46. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007; 115(2): 173–179.
  47. Qing X, Furong W, Yunxia L, et al. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012; 11: 108.
  48. Ichimoto E, Jo K, Kobayashi Y, et al. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J. 2009; 73(9): 1669–1673.
  49. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006; 26(3): 287–292.
  50. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol. 2008; 127(2): 290–291.
  51. Ling W, Zhaohui Ni, Ben He, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008; 108(3): c176–c181.
  52. Makris K, Markou N, Evodia E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med. 2009; 47(1): 79–82.
  53. Gansevoort RT, Matsushita K, van der Velde M, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011; 80(1): 93–104.
  54. van der Velde M, Matsushita K, Coresh J, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011; 79(12): 1341–1352.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k. ul. Świętokrzyska 73, 80–180 Gdańsk

tel.: +48 58 320 94 94, faks:+48 58 320 94 60,  e-mail: viamedica@viamedica.pl